Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: A focus on the factor V Leiden mutation

Thrombosis and Haemostasis

Volumn 76, Issue 4, 1996, Pages 510-513

  Manten, Bert ^a   Westendorp, Rudi G J ^a,b   Koster, Ted ^a   Reitsma, Pieter H ^a   Rosendaal, Frits R ^a  

^a Department of Clinical Epidemiology ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5;

ADULT; AGED; ARTICLE; BLOOD CLOTTING FACTOR 5 DEFICIENCY; CLINICAL FEATURE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR; SURGERY; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0029828615     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650613     Document Type: Article

References (17)

1. Weinmann EE, Salzman EW. Deep- vein thrombosis. N Engl J Med 1994; 331: 630-41.
2. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation associated with resistance to activated protein C. Nature 1994; 369: 64-7.
3. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
4. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thromboembolism due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
5. Loeliger EA, van Dijk- Wierda CA, van den Besselaar AMHP, Broekmans AW, Roos J. Anticoagulant therapy and the risk of bleeding; organizational infrastructure. In: Meade TW, ed. Anticoagulants and myocardial infarction; a reappraisal. Chicester, John Wiley and sons, 1984: 157.
6. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
7. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Hemostasis and Thrombosis: basic principles and practice. Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. 3rd ed. Philadelphia; J B Lippincott 1994: 1275-96.
8. Monréal M, Ruiz J, Olazabal A, Arias A, Roca J. Deep venous thrombosis and the risk of pulmonary embolism. Chest 1992; 102: 677-81.
9. Moser KM, Le Moine JR. Is embolic risk conditioned by location of deep venous thrombosis? Ann Int Med 1981; 94: 439-44.
10. Philbrick JT, Becker DM. Calf deep venous thrombosis: a wolf in sheep's clothing? Arch Intern Med 1988; 148: 2131-8.
11. Desmarais S, de Moerloose P, Reber G, Minazio A, Bounameaux H. Resistance to activated protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 1374-5.
12. Hull RD, Hirsh J, Carter CJ, Jay RM, Dodd PE, Ockelford PA, Coates G, Gill GJ, Turpie AG, Doyle DJ, Buller HR, Raskob GE. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Int Med 1983; 98: 891-9.
13. Quinn DA, Thompson T, Terrin ML, Thrall JH, Athanasoulis CA, McKusick KA, Stein PD, Hales CA. A prospective investigation of pulmonary embolism in women and men. JAMA 1992; 268: 1689-96.
14. Hull RD, Hirsh J, Carter CJ, Raskob GE, Gill GJ, Jay RM, Leclerc JR, David M, Coates G. Diagnostic value of ventilation- perfusion lung scanning in patients with suspected pulmonary embolism. Chest 1985; 88: 819-28.
15. Dahlbäck B. Inherited thrombophilia: resistance to activated protein C as a pathogenic factor of venous thromboembolism. Blood 1995; 85: 607-14.
16. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer ML, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thromboembolism in apparently healthy men. N Engl J Med 1995; 332: 912-7.
17. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral- contraceptive users who are carrier of factor V Leiden mutation. Lancet 1994; 344: 1453-7.